Intercept Pharmaceuticals Profit Margin

Intercept Pharmaceuticals posts a profit margin of -20.49% as of September 2023. That compares with 62.47% in the prior-year period — down 132.8% year over year. That is below the Healthcare sector average of 13.76%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Intercept Pharmaceuticals's profit margin was 62.47%. The latest reading is -20.49% — a 132.8% year-over-year decrease (period ending September 2023). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 13.76% is typical. Intercept Pharmaceuticals's -20.49% is lower that level. That is roughly 248.9% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Intercept Pharmaceuticals's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -20.49% as of September 2023; use YoY and peer views to separate noise from signal.

Context for ICPT's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 13.76%), and (3) consistency with growth and profitability. This page covers the first two; Intercept Pharmaceuticals's other metric pages and overview cover the third.